TY - JOUR T1 - Genomic epidemiology of SARS-CoV-2 transmission lineages in Ecuador JF - medRxiv DO - 10.1101/2021.03.31.21254685 SP - 2021.03.31.21254685 AU - Bernardo Gutierrez AU - Sully Márquez AU - Belén Prado-Vivar AU - Mónica Becerra-Wong AU - Juan José Guadalupe AU - Darlan da Silva Candido AU - Juan Carlos Fernandez-Cadena AU - Gabriel Morey-Leon AU - Rubén Armas-Gonzalez AU - Derly Madeleiny Andrade-Molina AU - Alfredo Bruno AU - Domenica de Mora AU - Maritza Olmedo AU - Denisse Portugal AU - Manuel Gonzalez AU - Alberto Orlando AU - Jan Felix Drexler AU - Andres Moreira-Soto AU - Anna-Lena Sander AU - Sebastian Brünink AU - Arne Kühne AU - Leandro Patiño AU - Andrés Carrazco-Montalvo AU - Orson Mestanza AU - Jeannete Zurita AU - Gabriela Sevillano AU - Louis du Plessis AU - John T. McCrone AU - Josefina Coloma AU - Gabriel Trueba AU - Verónica Barragán AU - Patricio Rojas-Silva AU - Michelle Grunauer AU - Moritz U.G. Kraemer AU - Nuno R. Faria AU - Marina Escalera-Zamudio AU - Oliver G. Pybus AU - Paúl Cárdenas Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/05/2021.03.31.21254685.abstract N2 - Characterisation of SARS-CoV-2 genetic diversity through space and time can reveal trends in virus importation and domestic circulation, and permit the exploration of questions regarding the early transmission dynamics. Here we present a detailed description of SARS-CoV-2 genomic epidemiology in Ecuador, one of the hardest hit countries during the early stages of the COVID-19 pandemic. We generate and analyse 160 whole genome sequences sampled from all provinces of Ecuador in 2020. Molecular clock and phylgeographic analysis of these sequences in the context of global SARS-CoV-2 diversity enable us to identify and characterise individual transmission lineages within Ecuador, explore their spatiotemporal distributions, and consider their introduction and domestic circulation. Our results reveal a pattern of multiple international importations across the country, with apparent differences between key provinces. Transmission lineages were mostly introduced before the implementation of non-pharmaceutical interventions (NPIs), with differential degrees of persistence and national dissemination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFinancial support was provided by the Clarendon Fund and the Department of Zoology of the University of Oxford (D.S.C.); WT fellowship 204311/Z/16/Z and MRC-FAPESP awards MR/S0195/1 and 18/14389-0 (N.R.F.); Branco Weiss Fellowship and EU grant 874850 MOOD (M.U.G.K.); WT Collaborators Award 206298/Z/17/Z (J.T.M.); Leverhulme Trust ECR Fellowship ECF-2019-542 (M.E.Z.); the Oxford Martin School (O.G.P., M.U.G.K. and L.d.P.); and the NIH Global Health Equity Scholars award FIC D43TW010540 (P.C.). Additional funding was provided for sample sequencing by the USFQ Emergency Grants, the A2CARES Network and the Centre for Arbovirus Discovery, Diagnosis, Genomics and Epidemiology (CADDE).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CEISH-USFQ 255 (Comite de Etica de Investigacion en Seres Humanos-USFQ): IE-JP067-2020-CEISH-256 USFQ; Ministerio de Salud Publica Comite Expedito (021-2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe newly generated sequences have been publicly shared through the GISAID platform. The data sets (including Ministry of Health and National Institute of Statistics and Census data) and code used to generate the analyses presented in this study, as well as a list of accession numbers for the Ecuador SARS-CoV-2 genome sequences analysed here are available through GitHub at https://github.com/BernardoGG/SARS-CoV-2_Genomic_lineages_Ecuador. We thank Andres N. Robalino and Carlos Oporto for their contribution to the open licence Ecuacovid repository (https://github.com/andrab/ecuacovid) used to extract epidemiological data for this study.https://github.com/BernardoGG/SARS-CoV-2_Genomic_lineages_Ecuadorhttps://github.com/andrab/ecuacovid ER -